MorphoSys Archives -

MorphoSys slims down, narrowing its focus to cancer

Phil Taylor HIBio, Immunology and inflammation, licensing, MorphoSys, nephrology, Oncology, partnering 0 Comment

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in

MorphoSys slims down, narrowing its focus to cancer

https://pharmaphorum.com/news/morphosys-slims-down-narrowing-its-focus-to-cancer/

News/ News/ Oncology

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

Phil Taylor CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab 0 Comment

Incyte and MorphoSys’ antibody therapy tafasitamab has been approved in Europe, promising to provide a more convenient alternative

Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU

https://pharmaphorum.com/news/incyte-morphosys-car-t-rival-tafasitamab-approved-in-eu/

News/ News/ R&D

MorphoSys offers $1.7bn for Constellation, but investors see stars

Phil Taylor Constellation Pharmaceuticals, Haematology, M&A, MorphoSys, myelofibrosis, Oncology, solid tumours 0 Comment

Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to

MorphoSys offers $1.7bn for Constellation, but investors see stars

https://pharmaphorum.com/news/morphosys-offers-1-7bn-for-constellation-but-investors-see-stars/

News/ News/ Oncology

Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody

Richard Staines cancer, DLBCL, Incyte, MorphoSys, non-Hodgkin lymphoma 0 Comment

Incyte and Morphosys’ Monjuvi antibody therapy has been approved for certain patients with lymphoma, as the companies hope

Incyte/Morphosys take on CAR-Ts with $198,000 per year antibody

https://pharmaphorum.com/news/incyte-morphosys-take-on-car-ts-as-lymphoma-antibody-monjuvi-approved-in-us/

News/ News/ News/ Oncology/ R&D

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Phil Taylor antibody, Incyte, MorphoSys, non-Hodgkin lymphoma, Oncology 0 Comment

Incyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

https://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/

News

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

George Underwood atopic dermatitis, eczema, Galapagos, MorphoSys, Novatis 0 Comment

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

https://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/

News/ News/ Oncology

Morphosys to take on CAR-Ts in NHL with promising antibody

Richard Staines MorphoSys, non-Hodgkin lymphoma 0 Comment

Germany’s Morphosys has announced results from its combination therapy of an experimental antibody and Celgene’s Revlimid in a

Morphosys to take on CAR-Ts in NHL with promising antibody

https://pharmaphorum.com/news/morphosys-to-take-on-car-ts-in-nhl-with-promising-antibody/

News

Novartis pays up to $1 billion for potential eczema drug

Piotr Wnuk dermatology, Galapagos, immunology, MOR106, MorphoSys, Novartis 0 Comment

Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to

Novartis pays up to $1 billion for potential eczema drug

https://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/

Trending

MorphoSys

Login